The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-07), BioPharma Credit's 9-Day RSI is 57.80.
The industry rank for BioPharma Credit's 9-Day RSI or its related term are showing as below:
LSE:BPCR's 9-Day RSI is ranked worse than 59.33% of 1699
companies
in the Asset Management industry
Industry Median: 54.22
vs LSE:BPCR: 57.80
BioPharma Credit (LSE:BPCR) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
BioPharma Credit 9-Day RSI Related Terms
LSE:BPCR vs BLK, BX, KKR: 9-Day RSI Comparison
For the Asset Management subindustry, BioPharma Credit's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit 9-Day RSI vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a 9-Day RSI of 57.80 as of Jul. 07, 2026. According to the industry distribution chart, BioPharma Credit ranks #1008 out of 1699 companies in the Asset Management industry, placing it in the top 59.3%.
Is BioPharma Credit's 9-Day RSI too high?
BioPharma Credit's current 9-Day RSI is 57.80. The Asset Management industry median 9-Day RSI is 54.22. BioPharma Credit's value of 57.80 is 6.6% above this industry median. Based on the distribution chart, BioPharma Credit ranks #1008 out of 1699 companies in the Asset Management industry, which is below the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's 9-Day RSI compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #1008 out of 1699 companies for 9-Day RSI. This places BioPharma Credit in the lower half of its industry. The industry median 9-Day RSI is 54.22. BioPharma Credit's value of 57.80 is 6.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for an Asset Management company?
The median 9-Day RSI among Asset Management companies is 54.22, based on 1,699 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current 9-Day RSI of 57.80 is 6.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Asset Management industry, the median 9-Day RSI is 54.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current 9-Day RSI is 57.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.96 — trading 0.2% above its estimated fair value. The current 9-Day RSI is 57.80 and 6.6% above the Asset Management industry median of 54.22. BioPharma Credit's overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current 9-Day RSI is 57.80 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued.
The current stock price of $0.96 is trading 0.2% above its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
9-Day RSI: 57.80
GF Value™: $0.96 vs. price of $0.96 (0.2% above fair value)
Industry Position: 6.6% above the Asset Management median (#1008 of 1699)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
52GF Score
Get the complete analysis for LSE:BPCR
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 